GUNG-HO PHARMA R&D INVESTMENTS SURPASS 3B   While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others.  The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore 1.43 billion in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore 3.03 billion after considering the cumulative expenditure by other small and medium players of the India pharma industry   . For Feedback, please email us at : communicationsmmactiv.com --